|Bid||135.600 x 900|
|Ask||135.970 x 800|
|Day's Range||135.71 - 140.86|
|52 Week Range||75.78 - 208.95|
|Beta (3Y Monthly)||3.30|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 27, 2019 - Mar 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||203.90|
“Value has performed relatively poorly since the 2017 shift, but we believe challenges to the S&P 500’s dominance are mounting and resulting active opportunities away from the index are growing. At some point, this fault line will break, likely on the back of rising rates, and all investors will be reminded that the best time […]
NEW YORK, Nov. 29, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
In some ways, this is the most exciting FDA approval of the year, but don't look for blockbuster sales.
NEW YORK, NY / ACCESSWIRE / November 28, 2018 / Loxo Oncology and ACADIA Pharmaceuticals were two biotech stocks sinking on Tuesday. Traders showed their concern over ACADIA pricing a public offering of ...
The FDA announced approval Monday of Loxo Oncology Inc (NASDAQ: LOXO ) and Bayer AG (OTC: BAYRY ) Vitrakvi — chemically larotrectinib — for adults and pediatric patients with advanced or metastatic solid ...
Bayer (BAYRY) receives the FDA approval for larotrectinib for the treatment of adult and pediatric patients having solid tumors with NTRK gene fusion.
NEW YORK, NY / ACCESSWIRE / November 27, 2018 / Wall Street closed up on Monday as oil prices stabilized and giant tech stocks such as the FAANG (Facebook, Amazon, Apple, Netflix and Google-parent Alphabet), ...
A Loxo Oncology Inc drug shown to be effective against a wide variety of cancers driven by a single, rare genetic mutation has won U.S. approval, the Food and Drug Administration announced on Monday. The drug, larotrectinib, will be sold under the brand name Vitrakvi and priced at $32,800 per month, in partnership with Bayer AG. Kevin O'Leary, Bayer's vice president of pricing and contracting, said Bayer and Loxo will assist patients financially and offer a value-based program, refunding both out-of-pocket and insurer payments for patients who do not see a clinical benefit within the first three months of treatment.
The U.S. Food and Drug Administration (FDA) today approved Vitrakvi® (larotrectinib), the first ever oral TRK inhibitor, for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.1,2 This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on November 6. Index (PMI) data, output in the Healthcare sector is rising.
NEW YORK, NY / ACCESSWIRE / November 16, 2018 / U.S. equities regained footing on Thursday as oil prices climbed and hopes of a trade agreement between the U.S. and China raised investor’s optimism. The ...
Loxo (LOXO) delivered earnings and revenue surprises of -3128.57% and -1.35%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Stamford, Connecticut-based company said it had a loss of 89 cents. Losses, adjusted for non-recurring gains, were $2.26 per share. The developer of cancer treatments posted revenue ...
Larotrectinib New Drug Application (NDA) PDUFA date is November 26, 2018 LOXO-292 Registrational Data Expected in 2019 LOXO-292 NDA Submission Expected in Late 2019.
STAMFORD, Conn., Nov. 06, 2018 -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined.
NEW YORK, NY / ACCESSWIRE / November 5, 2018 / U.S. equities rolled back on Friday, ending a 3-day consecutive gain after confusing headlines about the trade talks with China. President Trump announced ...
NEW YORK, NY / ACCESSWIRE / November 2, 2018 / U.S. markets rallied on Thursday, with the S&P 500 Index logging its first 3-day win streak in six weeks, as trade concerns between the U.S. and China continued ...
STAMFORD, Conn., Nov. 01, 2018 -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined.
Mirati Therapeutics and Clovis Oncology dragged biotech companies into a pitfall Monday after studies of their cancer treatments disappointed during a meeting in Europe.